A Phase Ib/II Randomized Double-blind Placebo Controlled Trial Evaluating the Effect of Nivolumab for Patients With In-transit Melanoma Metastases Treated With Isolated Limb Perfusion - the NivoILP Trial
Phase of Trial: Phase I/II
Latest Information Update: 04 Mar 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Melphalan; Tasonermin
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NivoILP
- 28 Feb 2019 Planned initiation date (estimated date of first participant enrollement) changed from 1 Dec 2018 to 1 Apr 2019.
- 28 Feb 2019 Status changed from not yet recruiting to recruiting.
- 03 Oct 2018 New trial record